中文網
Taipei
Mon, Jan 24, 2022
01:31
light rain
18°C
CONNECT WITH US
Related company info
Jay Liu, Taipei; Eifeh Strom, DIGITIMES
Friday 22 October 2021
  • Apex Biotechnology
  • Performance
    The company's stock price closed at NT$26.55 on the TSE on Thursday, January 20, 2022.
    The company has reported consolidated revenues of NT$198 million for December 2021, representing a 0.1% increase on month and 31.9% increase on year.
    For the third quarter of 2021, the company totaled NT$509 million in consolidated revenues, up 5.2% sequentially and down 0% on year.
    Brief

    Full name: Apex Biotechnology

    Chinese name: 五鼎生物技術股份有限公司

    Short name: Apex

    Stock code: 1733

    Tax ID: 16130182

    Market: TSE

    Established: 2 Dec 1997

    Paid in capital: NT$997.27 million

    Listed on TSE: 17 Sep 2001

    Website: www.apexbio.com

  • Latest stock
    Apex [1733] historical stock price (NT$)
    DateVolume (k)TransactionsValueOpenHighLowCloseChangeAskBid
    21-Jan 435 288 11,443,489 26.35 26.60 26.15 26.25-0.30-1.13% 26.25 26.35
    20-Jan 350 268 9,260,310 26.50 26.70 26.25 26.55-0.20-0.75% 26.50 26.55
    19-Jan 673 370 17,783,504 26.30 26.80 26.10 26.75+0.25+0.94% 26.75 26.80
    18-Jan 1,914 1,005 51,018,105 27.35 27.50 26.35 26.50-1.00-3.64% 26.50 26.55
    17-Jan 1,740 1,010 48,108,028 27.45 28.10 27.20 27.50+0.45+1.66% 27.45 27.50
    • Source: TSE, compiled by Digitimes
    Latest sales

    Apex: Consolidated revenues, Dec 2020 - Dec 2021 (NT$m)

    Month

    Sales

    M/M

    Y/Y

    YTD

    Y/Y

    Dec-21

    198

    0.1%

    31.9%

    2,132

    6.3%

    Nov-21

    198

    19.9%

    38.5%

    1,933

    4.2%

    Oct-21

    165

    (1.5%)

    2.2%

    1,735

    1.4%

    Sep-21

    168

    (1.2%)

    11.7%

    1,570

    1.3%

    Aug-21

    170

    (1.6%)

    2.4%

    1,403

    0.2%

    Jul-21

    172

    10.5%

    (11.2%)

    1,233

    (0.2%)

    Jun-21

    156

    (8.7%)

    (30.6%)

    1,061

    1.9%

    May-21

    171

    8.4%

    (1.6%)

    905

    10.8%

    Apr-21

    158

    (9.9%)

    20.5%

    734

    14.2%

    Mar-21

    175

    (16.7%)

    3%

    576

    12.6%

    Feb-21

    210

    10%

    6.4%

    401

    17.4%

    Jan-21

    191

    27.1%

    32.3%

    191

    32.3%

    Dec-20

    150

    5.2%

    (23%)

    2,005

    (8.8%)

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, January 2022

    Apex: Consolidated revenues, 3Q20 - 3Q21 (NT$m)

    Quarter

    Sales

    Q/Q

    Y/Y

    YTD

    Y/Y

    3Q-21

    509

    5.2%

    (0%)

    1,570

    1.3%

    2Q-21

    484

    (15.9%)

    (8.4%)

    1,061

    1.9%

    1Q-21

    576

    26.8%

    12.6%

    576

    12.6%

    4Q-20

    455

    (10.8%)

    (31.8%)

    2,005

    (8.8%)

    3Q-20

    510

    (3.7%)

    9.4%

    1,551

    1.2%

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, January 2022

    Latest balance sheet and income statement

    Apex: Consolidated balance sheet, 3Q20 - 3Q21 (NT$k)

    Item

    3Q-2021

    2Q-2021

    1Q-2021

    4Q-2020

    3Q-2020

    Current assets

    1,535,060

    1,705,282

    1,778,263

    1,684,472

    1,641,534

    Intangible assets

    112,051

    115,088

    123,172

    128,920

    136,660

    Non-current assets

    914,284

    926,466

    946,214

    966,970

    993,560

    Assets

    2,449,344

    2,631,748

    2,724,477

    2,651,442

    2,635,094

    Current liabilities

    657,086

    796,465

    923,643

    883,426

    894,782

    Non-current liabilities

    122,334

    120,075

    120,490

    121,849

    126,207

    Liabilities

    779,420

    916,540

    1,044,133

    1,005,275

    1,020,989

    Stockholders' equity

    1,669,924

    1,715,208

    1,680,344

    1,646,167

    1,614,105

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, January 2022

    Apex: Consolidated income statement, 3Q20 - 3Q21 (NT$k)

    Item

    3Q-2021

    2Q-2021

    1Q-2021

    4Q-2020

    3Q-2020

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    Operating revenue

    509,469

     

    484,485

     

    576,388

     

    454,730

     

    509,593

     

    Gross profit (loss) from operations

    148,630

    29.2%

    126,900

    26.2%

    150,468

    26.1%

    106,827

    23.5%

    118,555

    23.3%

    Operating expenses

    91,489

    18%

    89,586

    18.5%

    88,198

    15.3%

    80,320

    17.7%

    88,863

    17.4%

    Operating income (loss)

    57,141

    11.2%

    37,314

    7.7%

    62,270

    10.8%

    26,507

    5.8%

    29,692

    5.8%

    Non-operating expenses and losses

    3,832

    0.8%

    -12,177

    -2.5%

    -21,737

    -3.8%

    11,859

    2.6%

    -1,181

    -0.2%

    Income from continuing operations before income tax

    60,973

    12%

    25,137

    5.2%

    40,533

    7%

    38,366

    8.4%

    28,511

    5.6%

    Net income (loss)

    64,162

    12.6%

    22,528

    4.6%

    34,065

    5.9%

    33,054

    7.3%

    23,073

    4.5%

    Diluted earnings per share (NT$)

    0.6

     

    0.2

     

    0.3

     

     

     

    0.2

     

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, January 2022

  • Apex Biotechnology full profile

Global server revenue forecast, 2022

Global server shipment forecast, 2022

Taiwan LCD monitors - 3Q 2021

Global smartphone industry 2021 review

China records sales of 3.52 million NEVs in 2021; Nidec increases machine tool output in China; TSMC adjusts plans for Baoshan R&D center

Deployment of Japan-based automakers in Southeast Asia